JP2005506294A5 - - Google Patents

Download PDF

Info

Publication number
JP2005506294A5
JP2005506294A5 JP2002574974A JP2002574974A JP2005506294A5 JP 2005506294 A5 JP2005506294 A5 JP 2005506294A5 JP 2002574974 A JP2002574974 A JP 2002574974A JP 2002574974 A JP2002574974 A JP 2002574974A JP 2005506294 A5 JP2005506294 A5 JP 2005506294A5
Authority
JP
Japan
Prior art keywords
tegafur
use according
uracil
administered
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002574974A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005506294A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/006262 external-priority patent/WO2002076459A1/en
Publication of JP2005506294A publication Critical patent/JP2005506294A/ja
Publication of JP2005506294A5 publication Critical patent/JP2005506294A5/ja
Pending legal-status Critical Current

Links

JP2002574974A 2001-03-06 2002-03-04 テガフル、ウラシル、フォリン酸、パクリタキセルおよびカルボプラチンの投与による腫瘍の治療方法および剤形 Pending JP2005506294A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27357701P 2001-03-06 2001-03-06
PCT/US2002/006262 WO2002076459A1 (en) 2001-03-06 2002-03-04 Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin

Publications (2)

Publication Number Publication Date
JP2005506294A JP2005506294A (ja) 2005-03-03
JP2005506294A5 true JP2005506294A5 (enExample) 2005-12-22

Family

ID=23044526

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002574974A Pending JP2005506294A (ja) 2001-03-06 2002-03-04 テガフル、ウラシル、フォリン酸、パクリタキセルおよびカルボプラチンの投与による腫瘍の治療方法および剤形

Country Status (20)

Country Link
US (1) US6770653B2 (enExample)
EP (1) EP1368034A1 (enExample)
JP (1) JP2005506294A (enExample)
KR (1) KR20030081496A (enExample)
BR (1) BR0207443A (enExample)
CA (1) CA2439676A1 (enExample)
CZ (1) CZ20032266A3 (enExample)
EE (1) EE200300429A (enExample)
HR (1) HRP20030801A2 (enExample)
HU (1) HUP0303466A3 (enExample)
IL (1) IL157357A0 (enExample)
IS (1) IS6925A (enExample)
MX (1) MXPA03007989A (enExample)
NO (1) NO20033910L (enExample)
PL (1) PL363967A1 (enExample)
RU (1) RU2284184C2 (enExample)
SK (1) SK10602003A3 (enExample)
WO (1) WO2002076459A1 (enExample)
YU (1) YU69903A (enExample)
ZA (1) ZA200306541B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0115162A (pt) * 2000-11-06 2003-10-21 Pharma Mar Sa Tratamentos antitumorais eficazes
MXPA05009781A (es) 2003-03-14 2005-10-26 Taiho Pharmaceutical Co Ltd Potenciador de efecto antitumoral y agente antitumoral.
WO2004087105A1 (en) * 2003-04-02 2004-10-14 Celator Pharmaceuticals, Inc. Combination formulations of platinum agents and fluoropyrimidines
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
US20080255132A1 (en) * 2003-11-14 2008-10-16 Eric Rowinsky Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
KR20050099311A (ko) * 2004-04-09 2005-10-13 에이엔에이치 케어연구소(주) 주사제용 항암제 조성물
PL1827500T3 (pl) * 2004-10-26 2009-09-30 Pharma Mar Sa Pegylowana liposomalna doksorubicyna w kombinacji z ekteinascydyną 743
DK1658848T3 (da) 2004-10-29 2007-11-26 Pharma Mar Sa Formuleringer omfattende ecteinascidin og et disaccharid
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
SG166775A1 (en) 2005-02-18 2010-12-29 Abraxis Bioscience Llc Combinations and modes of administration of therapeutic agents and combination therapy
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
AU2008202078B2 (en) * 2007-10-10 2012-05-31 Wellkey Holdings Limited Stability of secondary metabolite mass production through synchronized plant cell cultures
AU2008313634A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Prognostic molecular markers for ET-743 treatment
CA2794147A1 (en) 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma
KR101894689B1 (ko) 2010-03-29 2018-09-04 아브락시스 바이오사이언스, 엘엘씨 암의 치료 방법
EP2575804A4 (en) 2010-06-04 2013-10-23 Abraxis Bioscience Llc METHOD FOR THE TREATMENT OF PANCREASCRE
AU2016250616B2 (en) * 2015-04-22 2021-01-21 Syn-Nat Products Enterprise LLC Co-crystal composition and its pharmaceutical use
AU2017319260B2 (en) 2016-08-31 2020-01-30 Fujifilm Corporation Anti-tumor agent, anti-tumor effect enhancer, and anti-tumor kit
RU2646450C1 (ru) * 2017-05-11 2018-03-05 Владимир Михайлович Курусин Способ лечения предраковых и ранних стадий раковых заболеваний желудка
WO2019146130A1 (ja) 2018-01-29 2019-08-01 富士フイルム株式会社 胆道がん用抗腫瘍剤および胆道がんの処置方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
US4328229A (en) 1978-03-29 1982-05-04 Taiho Pharmaceutical Company Limited Anti-cancer composition for delivering 5-fluorouracil to cancer tissues
US5534513A (en) 1991-09-05 1996-07-09 Taiho Pharmaceutical Company, Ltd. Antitumor potentiator and antitumor composition
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
RU2194541C1 (ru) * 2001-07-13 2002-12-20 Научно-исследовательский институт онкологии Томского научного центра СО РАН Способ комбинированного лечения больных местнораспространенным раком желудка

Similar Documents

Publication Publication Date Title
JP2005506294A5 (enExample)
RU2003129527A (ru) Способ и дозированная форма для опухолей путем введения тегафура, урацила, фолиновой кислоты, паклитаксела и карбоплатины
ES2630002T5 (es) Fármaco anticanceroso que contiene alfa,alfa,alfa-trifluorotimidina e inhibidor de timidina fosforilasa
US9814724B2 (en) Antitumor effect potentiator and antitumor agent
JP2004534850A5 (enExample)
JP2019503365A5 (enExample)
RU2003114752A (ru) Лечение желудочно-кишечных стромальных опухолей
JP2006515883A5 (enExample)
JP2009514874A5 (enExample)
FI3457135T3 (fi) Fabryn taudin hoitovaihtoehtoja
JP2002523502A5 (enExample)
JPH10279482A (ja) ピリミジン誘導体の単独で又は他の治療方法と組み合わせた癌の予防のための使用
JP2007514754A5 (enExample)
JP2007501809A5 (enExample)
CN107296811A (zh) 一种用于治疗胃癌的喹啉衍生物
JP2002525323A5 (enExample)
RU2003118411A (ru) Кристаллические производные 1-метилкарбапенема
US20210177850A1 (en) Method for treating cancer patients with severe renal impairment
JP2004533434A5 (enExample)
CA2641713A1 (en) Hydrate forms of amg706
ES2247060T3 (es) Producto que comprende un inhibidor de la transduccion de las señales de las proteinas g heterotrimericas en asociacion con un agente antihipertensor para una utilizacion terapeutica en el tratamiento de la hipertension arterial.
NZ514014A (en) Method of treating sleep apnoea
Choi et al. A case of pneumatosis intestinalis associated with sunitinib treatment for renal cell carcinoma
PT1634595E (pt) Derivados de n-fenilbenzamida como fármacos para o tratamento doença pulmonar obstativa crónica (dpoc)
US6620816B2 (en) Method for treating tumors by the administration of tegafur, uracil, folinic acid, and cyclophosphamide